Lexicon Genetics Incorporated, a biopharmaceutical company, engages in the discovery of functions and pharmaceutical utility of genes, and using those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. The company discovers the physiological and behavioral functions of genes to identify potential points of therapeutic intervention or drug targets using the gene knockout technology. It has advanced knockout-validated targets in drug discovery programs in various therapeutic areas, including diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company has strategic collaborations and alliances with Bristol-Myers Squibb Company for the discovery, development, and commercialization of novel small molecule drugs in the neuroscience field; with Genentech, Inc. for the discovery of the functions of therapeutic proteins and potential antibody targets identified through Genentech's internal drug discovery research and to discover and develop biotherapeutic drugs; with Organon to jointly discover, develop, and commercialize novel biotherapeutics; and with Takeda Pharmaceutical Company Limited for the discovery of new drugs for the treatment of high blood pressure. Lexicon Genetics was co-founded by Arthur T. Sands and Brian P. Zambrowicz. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
As of November 4, 2010, 337,565,589 shares of the registrant’s common stock, par value $0.001 per share, were outstanding